Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Upfront Treatment of Advanced Stage Follicular Lymphoma – A Case Study of Obinutuzumab in Hong Kong

20 Oct 2022OncologyHaematology

Stijn van den Borne, MSc

Share

This content is sponsored. It is intended for healthcare professionals only.

Obinutuzumab-based chemotherapy followed by maintenance after remission has become a new treatment option for follicular lymphoma (FL) where rituximab has been the longstanding standard of care.

Upfront Treatment of Advanced Stage Follicular Lymphoma - A Case Study of Obinutuzumab in Hong Kong

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026